A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Since 2006, DPP‐4 inhibitors have become established therapy for the treatment of type 2 diabetes. Despite sharing a common mechanism of action, considerable chemical diversity exists amongst members of the DPP‐4 inhibitor class, raising the question as to whether structural differences may result in differentiated enzyme inhibition and antihyperglycaemic activity.

[1]  D. Drucker,et al.  Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors , 2014, Endocrine reviews.

[2]  Søren Højsgaard,et al.  A Kenward-Roger approximation and parametric bootstrap methods for tests in linear mixed models: The R Package pbkrtest , 2014 .

[3]  Shinichi Ishii,et al.  A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. , 2013, Biochemical and biophysical research communications.

[4]  W. Metzler,et al.  Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation , 2008, Protein science : a publication of the Protein Society.

[5]  Vincent S Stoll,et al.  Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors. , 2006, Biochemistry.

[6]  N. Thornberry,et al.  Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement , 2009, Current medical research and opinion.

[7]  V. Fischer,et al.  Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans , 2009, Drug Metabolism and Disposition.

[8]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[9]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[10]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[11]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[12]  A. Nicholls,et al.  Automated ligand placement and refinement with a combined force field and shape potential. , 2006, Acta crystallographica. Section D, Biological crystallography.

[13]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[14]  H. Nar,et al.  8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. , 2007, Journal of medicinal chemistry.

[15]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[16]  E. Kang,et al.  Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis , 2016, Medicine.

[17]  Hideaki Shima,et al.  The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A , 2004, Biological chemistry.

[18]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[19]  D. Kassel,et al.  Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. , 2011, Journal of medicinal chemistry.

[20]  D. Tatosian,et al.  Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin , 2013, Diabetes Therapy.

[21]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[22]  H. Lebovitz,et al.  Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas , 2016, Diabetes, obesity & metabolism.

[23]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.

[24]  Biching Sang,et al.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.

[25]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[26]  C. Deacon,et al.  Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review , 2011, Diabetes, obesity & metabolism.